Bank predicts double blockbuster status for Novo obesity drug next year

Novo Nordisk's weight loss drug Wegovy could be heading for double blockbuster status as soon as next year, according to an analysis by Danske Bank, which has almost doubled its previous expectations for the medicine.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The obesity drug Wegovy, developed by Novo Nordisk, could reach double blockbuster status as soon as next year, estimates an analysis from Danske Bank, reports media PLX.AI.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs